RxDoctor Payments Data

Stephen Sawyer, MD

Cardiovascular Disease · Milwaukee, WINPI 1336679299

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 26 payments — averaging $64.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Heartflow, Inc.$220
  • Lantheus Medical Imaging, Inc.$109
  • Abiomed$70
  • Boston Scientific$68
  • Edwards Lifesciences$30
  • plus $47 from 2 others

What the payments were for

  • Travel & lodging$61237%
  • Food & beverage$1,06463%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$68,442
Medicare patients
636
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$67,951
JardianceEmpagliflozin54$57,537
EntrestoSacubitril/Valsartan50$52,497
XareltoRivaroxaban21$24,165
Metoprolol Succinate184$3,156
Bumetanide39$1,710
Atorvastatin Calcium140$1,707
Ezetimibe25$1,092
Losartan Potassium88$664
Rosuvastatin Calcium62$653
Furosemide100$585
Carvedilol60$520
Potassium Chloride11$430
Spironolactone77$353
Isosorbide Mononitrate ErIsosorbide Mononitrate21$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24$52,49750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →